Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones

A. Benova, M. Ferencakova, K. Bardova, J. Funda, J. Prochazka, F. Spoutil, T. Cajka, M. Dzubanova, T. Balcaen, G. Kerckhofs, W. Willekens, GH. van Lenthe, G. Alquicer, A. Pecinova, T. Mracek, O. Horakova, M. Rossmeisl, J. Kopecky, M. Tencerova

. 2022 ; 65 (-) : 101598. [pub] 20220911

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032845

OBJECTIVE: The use of thiazolidinediones (TZDs) as insulin sensitizers has been shown to have side effects including increased accumulation of bone marrow adipocytes (BMAds) associated with a higher fracture risk and bone loss. A novel TZD analog MSDC-0602K with low affinity to PPARγ has been developed to reduce adverse effects of TZD therapy. However, the effect of MSDC-0602K on bone phenotype and bone marrow mesenchymal stem cells (BM-MSCs) in relation to obesity has not been intensively studied yet. METHODS: Here, we investigated whether 8-week treatment with MSDC-0602K has a less detrimental effect on bone loss and BM-MSC properties in obese mice in comparison to first generation of TZDs, pioglitazone. Bone parameters (bone microstructure, bone marrow adiposity, bone strength) were examined by μCT and 3-point bending test. Primary BM-MSCs were isolated and measured for osteoblast and adipocyte differentiation. Cellular senescence, bioenergetic profiling, nutrient consumption and insulin signaling were also determined. RESULTS: The findings demonstrate that MSDC-0602K improved bone parameters along with increased proportion of smaller BMAds in tibia of obese mice when compared to pioglitazone. Further, primary BM-MSCs isolated from treated mice and human BM-MSCs revealed decreased adipocyte and higher osteoblast differentiation accompanied with less inflammatory and senescent phenotype induced by MSDC-0602K vs. pioglitazone. These changes were further reflected by increased glycolytic activity differently affecting glutamine and glucose cellular metabolism in MSDC-0602K-treated cells compared to pioglitazone, associated with higher osteogenesis. CONCLUSION: Our study provides novel insights into the action of MSDC-0602K in obese mice, characterized by the absence of detrimental effects on bone quality and BM-MSC metabolism when compared to classical TZDs and thus suggesting a potential therapeutical use of MSDC-0602K in both metabolic and bone diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032845
003      
CZ-PrNML
005      
20230131151818.0
007      
ta
008      
230120s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.molmet.2022.101598 $2 doi
035    __
$a (PubMed)36103974
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Benova, Andrea $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic; Faculty of Science, Charles University, Prague, Czech Republic
245    10
$a Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones / $c A. Benova, M. Ferencakova, K. Bardova, J. Funda, J. Prochazka, F. Spoutil, T. Cajka, M. Dzubanova, T. Balcaen, G. Kerckhofs, W. Willekens, GH. van Lenthe, G. Alquicer, A. Pecinova, T. Mracek, O. Horakova, M. Rossmeisl, J. Kopecky, M. Tencerova
520    9_
$a OBJECTIVE: The use of thiazolidinediones (TZDs) as insulin sensitizers has been shown to have side effects including increased accumulation of bone marrow adipocytes (BMAds) associated with a higher fracture risk and bone loss. A novel TZD analog MSDC-0602K with low affinity to PPARγ has been developed to reduce adverse effects of TZD therapy. However, the effect of MSDC-0602K on bone phenotype and bone marrow mesenchymal stem cells (BM-MSCs) in relation to obesity has not been intensively studied yet. METHODS: Here, we investigated whether 8-week treatment with MSDC-0602K has a less detrimental effect on bone loss and BM-MSC properties in obese mice in comparison to first generation of TZDs, pioglitazone. Bone parameters (bone microstructure, bone marrow adiposity, bone strength) were examined by μCT and 3-point bending test. Primary BM-MSCs were isolated and measured for osteoblast and adipocyte differentiation. Cellular senescence, bioenergetic profiling, nutrient consumption and insulin signaling were also determined. RESULTS: The findings demonstrate that MSDC-0602K improved bone parameters along with increased proportion of smaller BMAds in tibia of obese mice when compared to pioglitazone. Further, primary BM-MSCs isolated from treated mice and human BM-MSCs revealed decreased adipocyte and higher osteoblast differentiation accompanied with less inflammatory and senescent phenotype induced by MSDC-0602K vs. pioglitazone. These changes were further reflected by increased glycolytic activity differently affecting glutamine and glucose cellular metabolism in MSDC-0602K-treated cells compared to pioglitazone, associated with higher osteogenesis. CONCLUSION: Our study provides novel insights into the action of MSDC-0602K in obese mice, characterized by the absence of detrimental effects on bone quality and BM-MSC metabolism when compared to classical TZDs and thus suggesting a potential therapeutical use of MSDC-0602K in both metabolic and bone diseases.
650    _2
$a zvířata $7 D000818
650    _2
$a antigen stromálních buněk kostní dřeně $x metabolismus $x farmakologie $7 D000074010
650    _2
$a glukosa $x metabolismus $7 D005947
650    _2
$a glutamin $x metabolismus $7 D005973
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x farmakologie $7 D007004
650    _2
$a inzulin $x metabolismus $7 D007328
650    12
$a mezenchymální kmenové buňky $x metabolismus $7 D059630
650    _2
$a myši $7 D051379
650    _2
$a myši obézní $7 D008820
650    _2
$a obezita $x farmakoterapie $x metabolismus $7 D009765
650    _2
$a PPAR gama $x metabolismus $7 D047495
650    _2
$a pioglitazon $x metabolismus $x farmakologie $7 D000077205
650    _2
$a spirosloučeniny $7 D013141
650    12
$a thiazolidindiony $x farmakologie $7 D045162
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ferencakova, Michaela $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Bardova, Kristina $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Funda, Jiri $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Prochazka, Jan $u Czech Centre for Phenogenomics & Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Spoutil, Frantisek $u Czech Centre for Phenogenomics & Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Cajka, Tomas $u Laboratory of Translational Metabolism, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Dzubanova, Martina $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic; Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Balcaen, Tim $u Biomechanics lab, Institute of Mechanics, Materials, and Civil Engineering, UCLouvain, Louvain-la-Neuve, Belgium; Pole of Morphology, Institute for Experimental and Clinical Research, UCLouvain, Brussels, Belgium; Department of Chemistry, Molecular Design and Synthesis, KU Leuven, Leuven, Belgium
700    1_
$a Kerckhofs, Greet $u Biomechanics lab, Institute of Mechanics, Materials, and Civil Engineering, UCLouvain, Louvain-la-Neuve, Belgium; Department of Materials Engineering, KU Leuven, Belgium; Prometheus, Division of Skeletal Tissue Engineering, Katholieke Universiteit Leuven, 3000 Leuven, Belgium; Pole of Morphology, Institute for Experimental and Clinical Research, UCLouvain, Brussels, Belgium
700    1_
$a Willekens, Wouter $u FIBEr, KU Leuven, Leuven, Belgium
700    1_
$a van Lenthe, G Harry $u Department of Mechanical Engineering, KU Leuven, Leuven, Belgium
700    1_
$a Alquicer, Glenda $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Pecinova, Alena $u Laboratory of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Mracek, Tomas $u Laboratory of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Horakova, Olga $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Rossmeisl, Martin $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Kopecky, Jan $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic
700    1_
$a Tencerova, Michaela $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Prague 142 20, Czech Republic. Electronic address: michaela.tencerova@fgu.cas.cz
773    0_
$w MED00190571 $t Molecular metabolism $x 2212-8778 $g Roč. 65, č. - (2022), s. 101598
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36103974 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151814 $b ABA008
999    __
$a ok $b bmc $g 1891530 $s 1184180
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 65 $c - $d 101598 $e 20220911 $i 2212-8778 $m Molecular metabolism $n Mol Metab $x MED00190571
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace